Emerging therapeutic targets in bladder cancer

Cancer Treatment Reviews

Volumn 41, Issue 2, 2015, Pages 170-178

  Carneiro, Benedito A ^a   Meeks, Joshua J ^a   Kuzel, Timothy M ^a   Scaranti, Mariana ^b   Abdulkadir, Sarki A ^a   Giles, Francis J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bladder cancer; Immunotherapy; Targeted therapy; Treatment; Urothelial bladder carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; AURORA KINASE; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; HEAT SHOCK PROTEIN; HYBRID PROTEIN; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; POLO LIKE KINASE 1; PROTEIN KINASE B; PROTEIN P53; T LYMPHOCYTE RECEPTOR; TRASTUZUMAB EMTANSINE; CD274 PROTEIN, HUMAN; CDK4 PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ERBB2 PROTEIN, HUMAN; FGFR1 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MAYTANSINE; MONOCLONAL ANTIBODY; MTOR PROTEIN, HUMAN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN SERINE THREONINE KINASE; TARGET OF RAPAMYCIN KINASE; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL CYCLE REGULATION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MOLECULARLY TARGETED THERAPY; PHENOTYPE; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; VIRUS ONCOGENE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GENE TRANSLOCATION; GENETICS; IMMUNOTHERAPY; METABOLISM; MUTATION; PATHOLOGY; PROCEDURES; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; AURORA KINASES; CARCINOMA, TRANSITIONAL CELL; CELL CYCLE PROTEINS; CLINICAL TRIALS AS TOPIC; CTLA-4 ANTIGEN; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOTHERAPY; MAYTANSINE; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 84921651021     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.11.003     Document Type: Review

References (126)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. Available from: ; 2013 [accessed 2013]. http://globocan.iarc.fr.
2. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64(1):9-29.
3. Burger M., Catto J.W., Dalbagni G., Grossman H.B., Herr H., Karakiewicz P., et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013, 63(2):234-241.
4. Sylvester R.J., van der Meijden A.P., Oosterlinck W., Witjes J.A., Bouffioux C., Denis L., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49(3):465-466. discussion 75-7.
5. Grossman H.B., Natale R.B., Tangen C.M., Speights V.O., Vogelzang N.J., Trump D.L., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003, 349(9):859-866.
6. von der Maase H., Sengelov L., Roberts J.T., Ricci S., Dogliotti L., Oliver T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005, 23(21):4602-4608.
7. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507(7492):315-22.
8. Beenken A., Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discovery 2009, 8(3):235-253.
9. Raju R, Palapetta SM, Sandhya VK, Sahu A, Alipoor A, Balakrishnan L. A network map of FGF-1/FGFR signaling system. 2014;2014:962962.
10. Pandey A., Gowda H., Wiedlocha A., Sorensen V. Signaling, internalization, and intracellular activity of fibroblast growth factor. J Signal Transduct 2004, 286:45-79.
11. Aigner A., Butscheid M., Kunkel P., Krause E., Lamszus K., Wellstein A., et al. An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release. Int J Cancer J Int Cancer 2001, 92(4):510-517.
12. Hacohen N., Kramer S., Sutherland D., Hiromi Y., Krasnow M.A. Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 1998, 92(2):253-263.
13. Sleeman M., Fraser J., McDonald M., Yuan S., White D., Grandison P., et al. Identification of a new fibroblast growth factor receptor, FGFR5. Gene 2001, 271(2):171-182.
14. Muenke M., Schell U., Hehr A., Robin N.H., Losken H.W., Schinzel A., et al. A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome. Nat Genet 1994, 8(3):269-274.
15. Dode C., Levilliers J., Dupont J.M., De Paepe A., Le Du N., Soussi-Yanicostas N., et al. Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet 2003, 33(4):463-465.
16. Naski M.C., Wang Q., Xu J., Ornitz D.M. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 1996, 13(2):233-237.
17. Rand V., Huang J., Stockwell T., Ferriera S., Buzko O., Levy S., et al. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci USA 2005, 102(40):14344-14349.
18. Giri D., Ropiquet F., Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 1999, 5(5):1063-1071.
19. Antoniou A.C., Spurdle A.B., Sinilnikova O.M., Healey S., Pooley K.A., Schmutzler R.K., et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008, 82(4):937-948.
20. Chesi M., Nardini E., Brents L.A., Schrock E., Ried T., Kuehl W.M., et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997, 16(3):260-264.
21. Streit S., Bange J., Fichtner A., Ihrler S., Issing W., Ullrich A. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer J Int Cancer 2004, 111(2):213-217.
22. Cappellen D., De Oliveira C., Ricol D., de Medina S., Bourdin J., Sastre-Garau X., et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999, 23(1):18-20.
23. Sibley K., Cuthbert-Heavens D., Knowles M.A. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene 2001, 20(6):686-691.
24. di Martino E., Tomlinson D.C., Knowles M.A. A decade of FGF receptor research in bladder cancer: past, present, and future challenges. Adv Urol 2012, 2012:429213.
25. Helsten T.L.E., SK, Carter J., Kurzrock R. The FGFR landscape in cancer: an analysis of 4,869 cases. J Clin Oncol 2014, 32(5s). [abstr 11059].
26. Tomlinson D.C., Baldo O., Harnden P., Knowles M.A. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007, 213(1):91-98.
27. Gozgit J.M., Wong M.J., Moran L., Wardwell S., Mohemmad Q.K., Narasimhan N.I., et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 2012, 11(3):690-699.
28. Zhao G., Li W.Y., Chen D., Henry J.R., Li H.Y., Chen Z., et al. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol Cancer Ther 2011, 10(11):2200-2210.
29. Chell V., Balmanno K., Little A.S., Wilson M., Andrews S., Blockley L., et al. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene 2013, 32(25):3059-3070.
30. Bahleda R., Dienstmann R., Adamo B., Gazzah A., Infante J.R. Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors. J Clin Oncol 2014, 32(5s). [abstr 2501].
31. Du X., Xie Y., Xian C.J., Chen L. Role of FGFs/FGFRs in skeletal development and bone regeneration. J Cell Physiol 2012, 227(12):3731-3743.
32. Sequist LV, Cassier P, Varga A, Tabernero J, Schellens JHM, Delord J, et al. Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. In: Proceedings of the 105th annual meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego Philadelphia (PA): AACR; 2014 [Abstract nr CT326].
33. Tie J, Bang Y, Park YS, Kang Y, Monteith D, Hartsock K, et al. A phase I trial of LY2874455, a fibroblast growth factor receptor inhibitor, in patients with advanced cancer. In: Proceedings of the 105th annual meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego Philadelphia (PA): AACR; 2014 [Abstract nr CT215 2014].
34. Milowsky M.I., Dittrich C., Martinez I.D., Jagdev S., Millard F.E., Sweeney C., et al. Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3. J Clin Oncol 2013, 31(Suppl. 6). [abstr 255].
35. Platt F.M., Hurst C.D., Taylor C.F., Gregory W.M., Harnden P., Knowles M.A. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 2009, 15(19):6008-6017.
36. Askham J.M., Platt F., Chambers P.A., Snowden H., Taylor C.F., Knowles M.A. AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene 2010, 29(1):150-155.
37. Sjodahl G., Lauss M., Gudjonsson S., Liedberg F., Hallden C., Chebil G., et al. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS ONE 2011, 6(4):e18583.
38. Houede N., Pourquier P. Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers. Pharmacol Ther 2014.
39. Rodon J., Brana I., Siu L.L., De Jonge M.J., Homji N., Mills D., et al. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs 2014, 32(4):670-681.
40. Wu D., Tao J., Xu B., Qing W., Li P., Lu Q., et al. Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells. Urol Int 2011, 86(3):346-354.
41. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., et al. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66(3):1500-1508.
42. Moon du G., Lee S.E., Oh M.M., Lee S.C., Jeong S.J., Hong S.K., et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells. Int J Oncol 2014, 45(3):1027-1035.
43. Cirone P., Andresen C.J., Eswaraka J.R., Lappin P.B., Bagi C.M. Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer. Cancer Chemother Pharmacol 2014, 73(3):525-538.
44. Juric D., Soria J., Sharma S., Benerji U., Azaro A., Desai J., et al. A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors. J Clinical Oncol 2014, 32(5s). [abstr 9051].
45. Crul M., Rosing H., de Klerk G.J., Dubbelman R., Traiser M., Reichert S., et al. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 2002, 38(12):1615-1621.
46. Krawczyk J., Keane N., Swords R., O'Dwyer M., Freeman C.L., Giles F.J. Perifosine - a new option in treatment of acute myeloid leukemia?. Expert Opin Investig Drugs 2013, 22(10):1315-1327.
47. Davies B.R., Greenwood H., Dudley P., Crafter C., Yu D.H., Zhang J., et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther 2012, 11(4):873-887.
48. Milowsky M.I., Iyer G., Regazzi A.M., Al-Ahmadie H., Gerst S.R., Ostrovnaya I., et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int 2013, 112(4):462-470.
49. Iyer G., Hanrahan A.J., Milowsky M.I., Al-Ahmadie H., Scott S.N., Janakiraman M., et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012, 338(6104):221.
50. Seront E., Rottey S., Sautois B., Kerger J., D'Hondt L.A., Verschaeve V., et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol 2012, 23(10):2663-2670.
51. Gerullis H., Eimer C., Ecke T.H., Georgas E., Freitas C., Kastenholz S., et al. A phase II trial of temsirolimus in second-line metastatic urothelial cancer. Med Oncol 2012, 29(4):2870-2876.
52. Becker M.N., Wu K.J., Marlow L.A., Kreinest P.A., Vonroemeling C.A., Copland J.A., et al. The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro. Urol Oncol 2014, 32(3):317-326.
53. Fleischmann A., Rotzer D., Seiler R., Studer U.E., Thalmann G.N. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol 2011, 60(2):350-357.
54. Bose R., Kavuri S.M., Searleman A.C., Shen W., Shen D., Koboldt D.C., et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discovery 2013, 3(2):224-237.
55. Ross J.S., Wang K., Gay L.M., Al-Rohil R.N., Nazeer T., Sheehan C.E., et al. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin Cancer Res 2014, 20(1):68-75.
56. Tsai Y.S., Cheng H.L., Tzai T.S., Chow N.H. Clinical significance of ErbB receptor family in urothelial carcinoma of the bladder: a systematic review and meta-analysis. Adv Urol 2012, 2012:181964.
57. Erben P., Wirtz R.M., Martini T., Trunk M.J., Hofheinz R., Michel M.S., et al. Prognostic value of HER2 expression in patients with bladder cancer treated with radical cystectomy: a biomarker study. J Clin Oncol 2014, 32. [abstr e15515].
58. Hussain M.H., MacVicar G.R., Petrylak D.P., Dunn R.L., Vaishampayan U., Lara P.N., et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007, 25(16):2218-2224.
59. Wulfing C., Machiels J.P., Richel D.J., Grimm M.O., Treiber U., De Groot M.R., et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009, 115(13):2881-2890.
60. Hayashi T., Jaeger W., Moskalev I., Awrey S., Li N., Fazli L. Targeting HER2 with trastuzumab-DM1 (T-DM1) in HER2-overexpressing bladder cancer. J Urol 2014, 191(4s):e301.
61. Richards D.A., Braiteh F.S., Garcia A.A., Denlinger C.S., Conkling P.R., Edenfield W.J., et al. A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors. J Clin Oncol 2014, 32(5s). [abstr 651].
62. Bajorin D.F., Gomella L.G., Sharma P., Plimack E.R., O'Donnell P.H., Hoffman-Censits J.H., et al. Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence. J Clin Oncol 2014, 32(5s). [abstract 4541].
63. Zhou H., Kuang J., Zhong L., Kuo W.L., Gray J.W., Sahin A., et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998, 20(2):189-193.
64. Katayama H., Ota T., Jisaki F., Ueda Y., Tanaka T., Odashima S., et al. Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst 1999, 91(13):1160-1162.
65. Bischoff J.R., Anderson L., Zhu Y., Mossie K., Ng L., Souza B., et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998, 17(11):3052-3065.
66. Sen S., Zhou H., White R.A. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 1997, 14(18):2195-2200.
67. Reichardt W., Jung V., Brunner C., Klein A., Wemmert S., Romeike B.F., et al. The putative serine/threonine kinase gene STK15 on chromosome 20q13.2 is amplified in human gliomas. Oncol Rep 2003, 10(5):1275-1279.
68. Bufo P., Sanguedolce F., Tortorella S., Cormio L., Carrieri G., Pannone G. Expression of mitotic kinases phospho-aurora A and aurora B correlates with clinical and pathological parameters in bladder neoplasms. Histol Histopathol 2010, 25(11):1371-1377.
69. Comperat E., Bieche I., Dargere D., Laurendeau I., Vieillefond A., Benoit G., et al. Gene expression study of Aurora-A reveals implication during bladder carcinogenesis and increasing values in invasive urothelial cancer. Urology 2008, 72(4):873-877.
70. Giles F.J., Swords R.T., Nagler A., Hochhaus A., Ottmann O.G., Rizzieri D.A., et al. MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. Leukemia 2013, 27(1):113-117.
71. Zhou N., Singh K., Mir M.C., Parker Y., Lindner D., Dreicer R., et al. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res 2013, 19(7):1717-1728.
72. Dees E.C., Infante J.R., Cohen R.B., O'Neil B.H., Jones S., von Mehren M., et al. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011, 67(4):945-954.
73. Macarulla T., Cervantes A., Elez E., Rodriguez-Braun E., Baselga J., Rosello S., et al. Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther 2010, 9(10):2844-2852.
74. Weichert W., Schmidt M., Gekeler V., Denkert C., Stephan C., Jung K., et al. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 2004, 60(3):240-245.
75. Takai N., Hamanaka R., Yoshimatsu J., Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene 2005, 24(2):287-291.
76. Nogawa M., Yuasa T., Kimura S., Tanaka M., Kuroda J., Sato K., et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Investig 2005, 115(4):978-985.
77. Yamamoto Y., Matsuyama H., Kawauchi S., Matsumoto H., Nagao K., Ohmi C., et al. Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer. Oncology 2006, 70(3):231-237.
78. Golan A., Yudkovsky Y., Hershko A. The cyclin-ubiquitin ligase activity of cyclosome/APC is jointly activated by protein kinases Cdk1-cyclin B and Plk. J Biol Chem 2002, 277(18):15552-15557.
79. Sumara I., Vorlaufer E., Stukenberg P.T., Kelm O., Redemann N., Nigg E.A., et al. The dissociation of cohesin from chromosomes in prophase is regulated by polo-like kinase. Mol Cell 2002, 9(3):515-525.
80. Rudolph D., Steegmaier M., Hoffmann M., Grauert M., Baum A., Quant J., et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 2009, 15(9):3094-3102.
81. Schoffski P., Awada A., Dumez H., Gil T., Bartholomeus S., Wolter P., et al. A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 2012, 48(2):179-186.
82. Lin C.C., Su W.C., Yen C.J., Hsu C.H., Su W.P., Yeh K.H., et al. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. Br J Cancer 2014, 110(10):2434-2440.
83. Stadler W.M., Vaughn D.J., Sonpavde G., Vogelzang N.J., Tagawa S.T., Petrylak D.P., et al. An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer 2014, 120(7):976-982.
84. Dumez H., Gombos A., Schoffski P., Gil T., Vulsteke C., Meeus M., et al. Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors. J Clin Oncol 2012, 30. [abstract 3018].
85. Wu C, Sim H, Ambudkar SV. Human ABCB1 and ABCG2 confer acquired resistance to Polo-like kinase 1 inhibitors, BI 2536, volasertib and GSK641364. In: Proceedings of the 105th annual meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego Philadelphia (PA): AACR; 2014 [Abstract nr 766 2014].
86. Hepburn A.C., Veeratterapillay R., Williamson S.C., El-Sherif A., Sahay N., Thomas H.D., et al. Side population in human non-muscle invasive bladder cancer enriches for cancer stem cells that are maintained by MAPK signalling. PLoS ONE 2012, 7(11):e50690.
87. Ramanathan RK, Hamburg SI, Borad MJ, Seetharam M, Kundranda MN, Lee P, et al. A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors. In: Proceedings of the 104th annual meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC, Philadelphia (PA): AACR; 2013 [Abstract nr LB-289].
88. Hikichi Y., Honda K., Hikami K., Miyashita H., Kaieda I., Murai S., et al. TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Mol Cancer Ther 2012, 11(3):700-709.
89. van der Meer R., Yong Song H., Park S.H., Abdulkadir S.A., Roh M. RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition. Clinical cancer research: an official journal of the American Association for. Cancer Res 2014, 20(12):3211-3221.
90. Malumbres M., Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009, 9(3):153-166.
91. Baker S.J., Reddy E.P. CDK4: a key player in the cell cycle, development, and cancer. Genes & Cancer 2012, 3(11-12):658-669.
92. Italiano A., Bianchini L., Gjernes E., Keslair F., Ranchere-Vince D., Dumollard J.M., et al. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res 2009, 15(18):5696-5703.
93. Kopparapu P.K., Boorjian S.A., Robinson B.D., Downes M., Gudas L.J., Mongan N.P., et al. Expression of cyclin d1 and its association with disease characteristics in bladder cancer. Anticancer Res 2013, 33(12):5235-5242.
94. Lee C.C., Yamamoto S., Morimura K., Wanibuchi H., Nishisaka N., Ikemoto S., et al. Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer 1997, 79(4):780-789.
95. Fristrup N., Birkenkamp-Demtroder K., Reinert T., Sanchez-Carbayo M., Segersten U., Malmstrom P.U., et al. Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. Am J Pathol 2013, 182(2):339-349.
96. Berggren P., Kumar R., Sakano S., Hemminki L., Wada T., Steineck G., et al. Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR. Clin Cancer Res 2003, 9(1):235-242.
97. Chapman E.J., Harnden P., Chambers P., Johnston C., Knowles M.A. Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype. Clin Cancer Res 2005, 11(16):5740-5747.
98. Rebouissou S., Herault A., Letouze E., Neuzillet Y., Laplanche A., Ofualuka K., et al. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma. J Pathol 2012, 227(3):315-324.
99. Choi W., Porten S., Kim S., Willis D., Plimack E.R., Hoffman-Censits J., et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014, 25(2):152-165.
100. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18). In: Proceedings of the 105th annual meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego Philadelphia (PA): AACR; 2014 [Abstract nr CT101 2014].
101. Takashi M., Katsuno S., Sakata T., Ohshima S., Kato K. Different concentrations of two small stress proteins, alphaB crystallin and HSP27 in human urological tumor tissues. Urol Res 1998, 26(6):395-399.
102. Syrigos K.N., Harrington K.J., Karayiannakis A.J., Sekara E., Chatziyianni E., Syrigou E.I., et al. Clinical significance of heat shock protein-70 expression in bladder cancer. Urology 2003, 61(3):677-680.
103. Hadaschik B.A., Jackson J., Fazli L., Zoubeidi A., Burt H.M., Gleave M.E., et al. Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer. BJU Int 2008, 102(5):610-616.
104. Kamada M., So A., Muramaki M., Rocchi P., Beraldi E., Gleave M. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther 2007, 6(1):299-308.
105. Matsui Y., Hadaschik B.A., Fazli L., Andersen R.J., Gleave M.E., So A.I. Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer. Mol Cancer Ther 2009, 8(8):2402-2411.
106. So A.I., Black P.C., Chi K.N., Hurtado-Col A., Gleave M.E. A phase I trial of intravesical antisense oligonucleotide targeting heat shock protein 27 (OGX-427) for the treatment of non-muscle-invasive bladder cancer. J Clin Oncol 2012, 30(5s). [abstr 286].
107. Yoshida S., Koga F., Tatokoro M., Kawakami S., Fujii Y., Kumagai J., et al. Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy. Cell Cycle 2011, 10(24):4291-4299.
108. Karkoulis P.K., Stravopodis D.J., Margaritis L.H., Voutsinas G.E. 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells. BMC Cancer 2010, 10:481.
109. Tatokoro M., Koga F., Yoshida S., Kawakami S., Fujii Y., Neckers L., et al. Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells. Int J Cancer 2012, 131(4):987-996.
110. Acquaviva J., He S., Zhang C., Jimenez J.P., Nagai M., Sang J., et al. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism. Mol Cancer Res 2014, 12(7):1042-1054.
111. Mukamel E., Shohat B., Servadio C. Immunological profile of patients with transitional cell carcinoma of the bladder. Br J Urol 1982, 54(1):11-15.
112. Loskog A., Ninalga C., Paul-Wetterberg G., de la Torre M., Malmstrom P.U., Totterman T.H. Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol 2007, 177(1):353-358.
113. Sharma P., Shen Y., Wen S., Yamada S., Jungbluth A.A., Gnjatic S., et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA 2007, 104(10):3967-3972.
114. Boorjian S.A., Sheinin Y., Crispen P.L., Farmer S.A., Lohse C.M., Kuntz S.M., et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res 2008, 14(15):4800-4808.
115. Powles T., Vogelzang N.J., Fine D.G., Eder J.P., Braiteh F.S., Loriot Y., et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). J Clin Oncol 2014, 32(5s). [abstr 5011].
116. Inman B.A., Sebo T.J., Frigola X., Dong H., Bergstralh E.J., Frank I., et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 2007, 109(8):1499-1505.
117. Drake C.G., Lipson E.J., Brahmer J.R. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014, 11(1):24-37.
118. Hodi F.S., Dranoff G. The biologic importance of tumor-infiltrating lymphocytes. J Cutan Pathol 2010, 37(Suppl 1):48-53.
119. Carthon B.C., Wolchok J.D., Yuan J., Kamat A., Ng Tang D.S., Sun J., et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 2010, 16(10):2861-2871.
120. Curran M.A., Montalvo W., Yagita H., Allison J.P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010, 107(9):4275-4280.
121. Duraiswamy J., Kaluza K.M., Freeman G.J., Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013, 73(12):3591-3603.
122. Wainwright D.A., Chang A.L., Dey M., Balyasnikova I.V., Kim C.K., Tobias A., et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 2014, 20(20):5290-5301.
123. Card K.F., Price-Schiavi S.A., Liu B., Thomson E., Nieves E., Belmont H., et al. A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity. Cancer Immunol Immunother 2004, 53(4):345-357.
124. *0201 complex, in patients with advanced malignancies. Clin Cancer Res 2011, 17(24):7765-7775.
125. Fishman M.N., Hadjenberg J., Kuzel T., Mahipal A., Rosser C.J., Landau D., et al. Phase I/II clinical trial of ALT-801 a T-cell receptor/IL-2 fusion protein plus gemcitabine and cisplatin in urothelial cancer. J Clin Oncol 2013, 31(6s). [abstr 271].
126. Malmstrom P.U., Loskog A.S., Lindqvist C.A., Mangsbo S.M., Fransson M., Wanders A., et al. AdCD40L immunogene therapy for bladder carcinoma - the first phase I/IIa trial. Clin Cancer Res 2010, 16(12):3279-3287.